Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy.

Deniz Can GuvenMelek Seren AksunTaha Koray SahinOktay Halit AktepeHasan Cagri YildirimHakan TabanFurkan CeylanNeyran KertmenZafer ArikOmer DizdarSaadettin KilickapSercan AksoySuayib YalcinMustafa Erman

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2021)

In this study, we observed VTE development in more than 10% of immunotherapy-treated patients and increased VTE risk in patients with poorer ECOG status. With the asymptomatic nature of VTEs in most cases, a high index of suspicion level for VTE is required in patients treated with immunotherapy.

Keyphrases

venous thromboembolism
end stage renal disease
newly diagnosed
chronic kidney disease
squamous cell carcinoma
small cell lung cancer
prognostic factors
peritoneal dialysis
papillary thyroid
patient reported outcomes
patient reported